Navigation Links
Tracking the Battle Against Breast Cancer With New Market Research

FARMINGTON, Conn., Jan. 29, 2013 /PRNewswire-iReach/ -- Breast cancer is the most diagnosed cancer in women and is the leading cause of death among women globally. Increased public awareness and improved screening have led to earlier diagnosis, significantly improving survival rates, particularly in younger women. Unfortunately, many early breast cancer growths are not associated with pain or discomfort, and therefore are first detected as abnormalities on mammograms before patients or healthcare providers notice them.


Global Information (GII) highlights three market research reports covering the breast cancer market, drug pipeline and partnering deal activities. The reports will help participating organizations benchmark their own developments against worldwide data, compare portfolio and therapy focus with peers, jumpstart competitive drug intelligence operations, and more.

Time is running out to register for the Molecular Med Tri-Con 2013, which will feature conference programs in the following channels: diagnostics, therapeutics, clinical, informatics, and cancer.

Molecular Med Tri-Con 2013| February 11 – 15, 2013 | San Francisco, CA

Visit to register today

Breast Cancer Drug Pipeline Update 2013

There are currently 351 companies plus partners who are developing 479 drugs targeting breast cancer across 247 different targets. In addition, there are 7 suspended drugs and another 185 drugs where development has been ceased.

This report provides world-wide drug pipeline information, delivered in an unbiased and independent pipeline progress analysis for each identified drug. Breast Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 247 different targets. These targets are further categorized on in the software application by 61 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.

An Executive Summary for this report and free sample pages from the full document are available at

Breast Cancer Diagnostic and Drug Technologies: Global Markets

The market for predictive diagnostic and drug technologies for breast cancer was valued at $21.2 billion in 2011. This figure is projected to reach nearly $24.1 billion in 2016, a five-year compound annual growth rate (CAGR) of 2.5%.

Breast cancer drugs accounted for $10.2 billion in 2011 and should total $11.2 billion in 2016, a CAGR of 1.9%. Quantitative immunofluorescence totaled $5.9 billion in 2011 and should reach $6.9 billion in 2016, a CAGR of 3.1%. Genomic analysis was worth $4.4 billion in 2011 and in 2016 should be worth nearly $5.2 billion, a CAGR of 3.1%. IHC and FISH accounted for nearly $678 million in 2011 and are expected to be worth nearly $788 million in 2016, a CAGR of 3.1%.

An Executive Summary for this report and free sample pages from the full document are available at

Breast Cancer Partnering 2007-2012

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report provides an analysis of breast cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors breast cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

An Executive Summary for this report and free sample pages from the full document are available at

For more market research highlights, technical research news and industry updates, please visit

About Global Information Inc. Global Information (GII) ( is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796,

News distributed by PR Newswire iReach:

SOURCE Global Information, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Precision motion tracking Thousands of cells at a time
2. Precision motion tracking - Thousands of cells at a time
3. Clinical technique sets new standard for speed in battle to prevent pandemic infection
4. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
5. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
6. MU researchers identify key plant immune response in fight against bacteria
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Nanosurgery and the fight against cancer: Major breakthrough at Polytechnique Montral
9. 3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court
10. Defending against chemical acts of terrorism
11. X-BODY BioSciences to Present Novel Methods of Selecting for Antibodies Against Targets on Live Cells at CHIs Protein Engineering Summit
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Global Stem Cells Group announced ... clinics in the cities of Arica and Iquique in northern Chile. The facilities are part ... offer the most advanced protocols and techniques in stem cell medicine to patients from around ...
(Date:11/30/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a leader in ... Business Act on Climate Pledge, alongside more than 140 companies ... Obama Administration to demonstrate an ongoing commitment to climate action ... COP21 Paris climate negotiations. ... Canada . --> BioAmber uses biotechnology to ...
(Date:11/30/2015)...  Culprits beware, a University at Albany research ... is taking crime scene fingerprint identification to a ... -->   --> Photo ... --> Halámek and his team ... concept for identifying whether a culprit is male ...
(Date:11/30/2015)... Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or ... Norman C.W. Wong to its Board of Directors to ... Zenith with a wealth of experience as co-founder of Resverlogix, ... --> --> Dr. Wong ... board of directors. Zenith,s long standing expertise in epigenetics and ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
Breaking Biology News(10 mins):